Tufin® (NYSE: TUFN), a company pioneering a policy-centric approach to security and IT operations, today announced that its Chief Technology Officer, Reuven Harrison, will host a speaking session entitled "Defenders Think in Lists; Attackers Think in Graphs” at the 2020 CloudNativeCon Europe event, taking place virtually on August 17.
Most of our digital infrastructure is at risk due to the gap that exists between attack and defense strategies. Attackers usually penetrate systems in a graph-like flow. They start by identifying an entry point and then use discovery techniques and lateral movement to reach the "crown jewels.” Security teams often protect their systems using checklists: vulnerabilities, misconfigurations, excess privileges, etc.
In this session, Reuven will discuss this gap, its causes and implications, and suggest a better approach which is based on network connectivity analysis combined with weakness analysis.
Reuven Harrison, Co-founder and Chief Technology Officer, Tufin
Session: "Defenders Think in Lists; Attackers Think in Graphs”
Monday, August 17, 2020 at 17:35 CEST / 11:35am EST
Join Reuven’s session here: https://cnsdeu20.sched.com/event/dh6S/defenders-think-in-lists-attackers-think-in-graphs-reuven-harrison-tufin
The Cloud Native Computing Foundation’s flagship conference gathers adopters and technologists from leading open source and cloud native communities.
Tufin (NYSE: TUFN) simplifies management of some of the largest, most complex networks in the world, consisting of thousands of firewall and network devices and emerging hybrid cloud infrastructures. Enterprises select the company’s Tufin Orchestration Suite™ to increase agility in the face of ever-changing business demands while maintaining a robust security posture. The Suite reduces the attack surface and meets the need for greater visibility into secure and reliable application connectivity. With over 2,000 customers since its inception, Tufin’s network security automation enables enterprises to implement changes in minutes instead of days, while improving their security posture and business agility.
Find out more at: www.tufin.com
Follow Tufin on Twitter: @TufinTech
Read more on Tufin’s blog: Suite Talk
View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005045/en/
WINNIPEG, MB, April 23, 2021 /CNW/ - Budget 2021 is the Government of Canada's plan to finish the fight against COVID-19 and ensure a robust economic recovery that is sustainable and inclusive of all Canadians. Today, the Honourable Mary Ng, Minister of Small Business, Export Promotion and International Trade, attended a fireside chat with Dayna Spiring, President and CEO of Economic Development Winnipeg, to discuss investments in small businesses and entrepreneurs from Budget 2021: A Recovery Plan for Jobs, Growth, and Resilience. The COVID-19 recession has disproportionately affected low-wage workers, young people, women and racialized Canadians. For businesses, it has been a two-speed recession, with some finding ways to pivot and succeed but many—especially small businesses—fighting to survive. Budget 2021 is a historic investment to finish the fight against the pandemic, address the specific wounds of the COVID-19 recession, put people first, create jobs, grow the middle class and set businesses on a track for long-term growth. Budget 2021 will ensure that Canada's future will be healthier, more equitable, greener and more prosperous.The discussion between Minister Ng and Ms. Spiring focused on the many measures proposed in the budget to help small businesses and entrepreneurs bridge through the pandemic and come back stronger after recovery. Minister Ng highlighted that this is the most small business–friendly budget in Canadian history. From extending emergency measures like the Canada Emergency Wage Subsidy and Canada Emergency Rent Subsidy to incentivizing rehiring in recovery through a new Canada Recovery Hiring Program, Budget 2021 includes significant investments to support businesses in getting online and hiring back workers, commits to decisive action on lowering credit card fees, and improves support for exporters. The Government of Canada's top priority remains protecting Canadians' health and safety, particularly during this third wave of the pandemic and given the more aggressive variants of the virus. Vaccine rollout is under way across Canada, with federal government support in every province and territory.
Budget 2021 is a plan to bridge Canadians and Canadian businesses through the crisis and towards a robust recovery. It will support almost 500,000 new training and work opportunities, including 215,000 opportunities for youth; support businesses in our most affected sectors, such as tourism and arts and culture; and accelerate investment and digital transformation at small and medium-sized businesses. Budget 2021 is a plan that puts Canada on track to meet its commitment to create 1 million jobs by the end of the year.Canada entered the pandemic in a strong fiscal position. This allowed the government to take quick, decisive and responsible action, supporting people and businesses, and put Canada where it needs to be for a successful and strong recovery. Quote"This is the time to lean in and build back a more innovative, inclusive and sustainable future. While providing Canadians with the support they need to get through the pandemic, we need to invest now to ensure Canada has a strong recovery and is set up for long-term, sustainable and inclusive growth. By throwing our full weight behind Canadians and Canadian businesses with this budget, we are doing the most responsible thing for our economy and our future." – The Honourable Mary Ng, Minister of Small Business, Export Promotion and International Trade
Quick factsBudget 2021 includes $101.4 billion over three years in proposed investments as part of the Government of Canada's growth plan that will create good jobs and support a resilient and inclusive recovery. Key measures include: Extending emergency supports to bridge Canadians and Canadian businesses through to recovery, including: Extending the Canada Emergency Wage Subsidy, the Canada Emergency Rent Subsidy and Lockdown Support until September 25, 2021. Introducing the new Canada Recovery Hiring Program for eligible employers that continue to experience qualifying declines in revenues relative to before the pandemic. Extending the number of weeks for important income support for Canadians, such as the Canada Recovery Benefit and the Canada Recovery Caregiving Benefit.Supporting small and medium-sized businesses through transformative programs, such as: Launching the new Canada Digital Adoption Program that will directly help over 160,000 businesses adopt new technology and get online. It will provide them with the advice they need to get the most of new technology with the help of 28,000 young Canadians who will be trained to work with them. Allowing Canadian small businesses to fully expense up to $1.5 million in capital investments in a broad range of assets, including digital technology and intellectual property. This represents an additional $2.2 billion investment in the growth of Canada's entrepreneurs over the next five years. Enhancing the Canada Small Business Financing Program: Increasing annual financing of $560 million, supporting approximately 2,900 additional small businesses. Amending the Canada Small Business Financing Act and its regulations by: Expanding loan class eligibility to include lending against intellectual property and start-up assets and expenses. Increasing the maximum loan amount from $350,000 to $500,000 and extending the loan coverage period from 10 to 15 years for equipment and leasehold improvements. Expanding borrower eligibility to include non-profit and charitable social enterprises. Introducing a new line of credit product to help with liquidity and cover short-term working capital needs. Supporting diverse entrepreneurs through additional investments to make our economy more inclusive, including further investments in the Women Entrepreneurship Strategy and the Black Entrepreneurship Program, and investments to support Indigenous entrepreneurs. Investing $30 billion over the next five years to establish a Canada-wide early learning and child care system, in partnership with provincial, territorial and Indigenous partners, which will help all families access affordable, high-quality and flexible child care, no matter where they live. Related productsBudget 2021: A Recovery Plan for Jobs, Growth, and ResilienceBudget 2021 Support for Small Business BackgrounderBudget speechAssociated linksFall Economic Statement 2020: Supporting Canadians and Fighting COVID-19 Canada's COVID-19 Economic Response PlanStay connectedFollow @CanadaBusiness on social media for business-related news: Twitter, Facebook
SOURCE Innovation, Science and Economic Development Canada
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) "Relief” today announced that NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.
The study is posted at https://clinicaltrials.gov/ct2/show/NCT04360096 . The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure. If promising results are seen in the inpatient setting, the trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the need for hospital admission.
Professor Jonathan Javitt, MD, MPH, CEO of NeuroRx said, "Now that we know VIP suppresses replication of the SARS-CoV-2 virus in human lung cells, based on the outstanding work of the Oswaldo Cruz Institute (Rio de Janeiro).1 We are optimistic that treatment with VIP will not only help patients on ventilators, but will help to stop the advancement of the virus in patients with earlier stages of COVID-19. By blocking cytokine synthesis in the lung cells and increasing the production of surfactant, which is key to the lung’s ability to transmit oxygen, we are hopeful that inhaled VIP will prove to be of clinical benefit across a wider array of patients suffering respiratory complications from COVID-19 infection.”
The clinical trial of the inhaled formulation of RLF-100 is expected to begin on or before September 1, 2020.
About VIP in Lung Injury
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the Alveolar Type II cell, which is critical for the transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.
COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells, but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.
Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and is essential for oxygen exchange. Other than RLF-100, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.
RLF-100 (aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief’s predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both Mondo and Relief have worked on the development of an inhaled formulation of aviptadil for several years. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of aviptadil.
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent (US8178489 formulation for aviptadil) for RLF-100 and proprietary manufacturing processes for its synthesis.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF.
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
1 Temerozo JR, Sacramenta Q, Fintelman-Rodriques N, et. al. The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells, decrease the production of proinflammatory cytokines, and VIP levels are associated with survival in severe Covid-19 patients doi: https://doi.org/10.1101/2020.07.25.220806. https://www.biorxiv.org/content/10.1101/2020.07.25.220806v2.full
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805006124/en/